Answers are grounded in this paper and cite their sources.
Ibrutinib shows durable single-agent efficacy in relapsed or refractory mantle-cell lymphoma. (Funded by Pharmacyclics and others; ClinicalTrials.gov number, NCT01236391.)
No takes yet. Share an insight, caveat, or question.
Wang et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: